Physician profile
Glen S Smith
NPI 1912096579
$477.54
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $420 · 2020: $22.05 · 2022: $35.93.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $79.65 | 2019 | |
| Pfizer INC. | $59.05 | 2019-2022 | |
| Amgen INC. | $57.94 | 2019 | |
| Glaxosmithkline, LLC. | $51.99 | 2019 | |
| Astellas Pharma US INC | $37.50 | 2019 | |
| Merck Sharp & Dohme LLC | $25.61 | 2019 | |
| Abbott Laboratories | $24.08 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $23.32 | 2019 | |
| Valeritas, INC. | $23.22 | 2019 | |
| Novo Nordisk INC | $22.05 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $18.20 | 2022 | |
| Janssen Pharmaceuticals, INC | $16.87 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.36 | 2019 | |
| Lilly USA, LLC | $12.94 | 2019 | |
| Sanofi Pasteur INC. | $11.76 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Glen Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.